HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has maintained a Buy rating on Travere Therapeutics (NASDAQ:TVTX) and increased the price target from $17 to $19. This adjustment reflects a positive outlook on the company's future performance.

April 24, 2024 | 6:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reaffirmed its Buy rating on Travere Therapeutics and raised the price target from $17 to $19, indicating a bullish outlook on the stock.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong vote of confidence in the company's future performance and growth prospects. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in the stock's price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100